Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orexigen Hopes FDA Sees The LIGHT On Contrave NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Contrave could be approved by FDA in 2014, making it the third obesity therapeutic to reach the market in the last two years. An interim analysis of the CV outcomes study LIGHT demonstrates a favorable risk-benefit profile, management said.

Advertisement

Related Content

CV Outcomes Trials: FDA Actions, Announcements Paint Conflicted Picture
Cardiovascular Outcomes Data Transparency Vexes FDA, Sponsors
CV Trials For Symptomatic Conditions Feasible But Not Always Practical, FDA Panel Says
Opioid Withdrawal’s Potential CV Risk Drives Advisory Panel For Constipation Drugs
If At First You Don’t Succeed, Try Dispute Resolution
Novo Nordisk Lays Out Obesity Commercial Strategy, Ahead of Liraglutide FDA Submission
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075092

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel